Skip to main content

Market Overview

The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.

Large-cap pharma names AstraZeneca plc (NYSE: AZN) and Novartis AG (NYSE: NVS) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir obtained full regulatory approval in Japan.

Moderna Inc (NASDAQ: MRNA) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273.

The following are the key events and catalysts that biotech investors need to watch in the coming week.  


  • Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14
  • American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15
  • 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16
  • Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16


Clovis Oncology Inc (NASDAQ: CLVS) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as a monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.

Clinical Readouts

ASGCT Conference Presentations

Abeona Therapeutics Inc (NASDAQ: ABEO) is due to present updated interim results from the Transpher A and Transpher B studies, Phase 1/2 trials of ABO-102 and ABO-101, respectively, in mucopolysaccharidosis type IIIA, aka as Sanfilippo syndrome type.

Rocket Pharmaceuticals Inc (NASDAQ: RCKT will present updated data from Phase 1/2 FANCOLEN-I study, which is evaluating the safety and efficacy of infusion of autologous CD34 + cells transduced with a lentiviral vector carrying the FANCA gene in patients with Fanconi anemia subtype A, and updates from the Phase 1 LAD-I study that is evaluating its investigational gene therapy RP-L201 to treat severe Leukocyte Adhesion Deficiency-I.

Avrobio Inc (NASDAQ: AVRO) is scheduled to make an oral presentation on new data from the Phase 2 trial of AVR-RD-01 for Fabry (Wednesday). The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. Another oral presentation on new data from a preclinical research program for a gene therapy for Pompe disease is also scheduled for Wednesday.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is due to present updated data from the first three cohorts of a Phase 1/2 study of DTX301 in treating ornithine transcarbamylase deficiency (Wednesday). The company will also present updated data from the confirmatory cohort from a Phase 1/2 study of DTX401 in glycogen storage disease Type 1a (Friday).

Pfizer Inc. (NYSE: PFE) will present Phase 1b data for PF-06939926 in Duchenne muscular dystrophy on Friday.

Krystal Biotech Inc (NASDAQ: KRYS) will present a poster on KB407, an HSV-1 based gene therapy vector, for the treatment of cystic fibrosis.

See Also: Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss

Other Readouts

Genocea Biosciences Inc (NASDAQ: GNCA) will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea's neoantigen cell therapy. (Tuesday)

Krystal Biotech is due to present at the SID meeting with results from a Phase 1/2 study of in vivo gene therapy KB105 for treating autosomal recessive congenital ichthyosis as well as results of a Phase 1/2 trial that is evaluating in vivo correction of dystrophic epidermolysis bullosa by direct cutaneous COL7A1 gene replacement.

Caladrius Biosciences Inc (NASDAQ: CLBS) will present at the SCAI meeting Thursday with full data from the ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction.

Constellation Pharmaceuticals Inc (NASDAQ: CNST) said abstracts of a presentation due at the June 11-14 European Hematology Association meeting will be made available Thursday. The abstract pertains to an interim update from the MANIFEST Phase 2 study that is evaluating CPI-0610 in myelofibrosis.

Auris Medical Holding Ltd (NASDAQ: EARS) is due to release top-line data in early May from the Phase 1b trial that is evaluating AM-201 in healthy volunteers. AM-201 is the company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.



  • Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open)
  • Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open)
  • Apyx Medical Corp (NASDAQ: APYX) (before the market open)
  • Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open)
  • bluebird bio Inc (NASDAQ: BLUE) (before the market open)
  • Sesen Bio Inc (NASDAQ: SESN) (before the market open)
  • Mylan NV (NASDAQ: MYL) (before the market open)
  • Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open)
  • Wave Life Sciences Ltd (NASDAQ: WVE) (before the market open)
  • Passage Bio Inc (NASDAQ: PASG) (before the market open)
  • Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open)
  • Oyster Point Pharma Inc (NASDAQ: OYST) (before the market open)
  • Recro Pharma Inc (NASDAQ: REPH) (before the market open)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open)
  • Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open)
  • Assertio Therapeutics Inc (NASDAQ: ASRT) (before the market open)
  • Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (before the market open)
  • Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (after the close)
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close)
  • 10X Genomics Inc (NASDAQ: TXG) (after the close)
  • Aimmune Therapeutics Inc (NASDAQ: AIMT) (after the close)
  • Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
  • Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (after the close)
  • Pulse Biosciences Inc (NASDAQ: PLSE) (after the close)
  • Matinas BioPharma Holdings Inc (NYSE: MTNB) (after the close)
  • CorMedix Inc. (NYSE: CRMD) (after the close)
  • Castle Biosciences Inc (NASDAQ: CSTL) (after the close)
  • Omeros Corporation (NASDAQ: OMER) (after the close)
  • Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) (after the close)
  • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close)
  • Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close)
  • Organogenesis Holdings Inc (NASDAQ: ORGO) (after the close)
  • Neos Therapeutics Inc (NASDAQ: NEOS) (after the close)
  • Retrophin In (NASDAQ: RTRX) (after the close)
  • Sangamo Therapeutics Inc (NASDAQ: SGMO) (after the close)
  • Rockwell Medical Inc (NASDAQ: RMTI) (after the close)
  • Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close)
  • Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close)
  • Misonix Inc (NASDAQ: MSON) (after the close)
  • Liquidia Technologies Inc (NASDAQ: LQDA) (after the close)
  • Cara Therapeutics Inc (NASDAQ: CARA) (after the close)
  • CymaBay Therapeutics Inc (NASDAQ: CBAY) (after the close)
  • ChemoCentryx Inc (NASDAQ: CCXI) (after the close)
  • DURECT Corporation (NASDAQ: DRRX) (after the close)
  • Endologix, Inc. (NASDAQ: ELGX) (after the close)
  • Exagen Inc (NASDAQ: XGN) (after the close)
  • Evolus Inc (NASDAQ: EOLS) (after the close)
  • Intersect ENT Inc (NASDAQ: XENT) (after the close)
  • Fate Therapeutics Inc (NASDAQ: FATE) (after the close)


  • BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open)
  • DarioHealth Corp (NASDAQ: DRIO) (before the market open)
  • Palatin Technologies, Inc. (NYSE: PT) (before the market open)
  • InspireMD Inc (NYSE: NSPR) (before the market open)
  • STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open)
  • BioNTech SE – ADR (NASDAQ: BNTX) (before the market open)
  • aTyr Pharma Inc (NASDAQ: LIFE) (after the close)
  • Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close)
  • Gossamer Bio Inc (NASDAQ: GOSS) (after the close)
  • Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (after the close)
  • Curis, Inc. (NASDAQ: CRIS) (after the close)
  • Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close)
  • OncoCyte Corp (NYSE: OCX) (after the close)
  • Shockwave Medical Inc (NASDAQ: SWAV) (after the close)
  • Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close)
  • Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)
  • TapImmune Inc. common stock (NASDAQ: MRKR) (after the close)


  • PDS Biotechnology Corp (NASDAQ: PDSB) (before the market open)
  • Veru Inc (NASDAQ: VERU) (before the market open)
  • Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open)
  • Applied Genetic Technologies Corp (NASDAQ: AGTC) (before the market open)
  • BioLife Solutions Inc (NASDAQ: BLFS) (after the close)
  • DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the close)
  • Viela Bio Inc (NASDAQ: VIE) (after the close)
  • Biocept Inc (NASDAQ: BIOC) (after the close)
  • Eyenovia Inc (NASDAQ: EYEN) (after the close)
  • Edap Tms SA (NASDAQ: EDAP) (after the close)
  • RA Medical Systems Inc (NYSE: RMED) (after the close)
  • TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close)


  • Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open)
  • ImmuCell Corporation (NASDAQ: ICCC) (before the market open)
  • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open)
  • Transenterix Inc (NYSE: TRXC) (before the market open)
  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) (before the market open)
  • Aptinyx Inc (NASDAQ: APTX) (after the close)
  • Aytu Bioscience Inc (NASDAQ: AYTU) (after the close)
  • Applied DNA Sciences Inc (NASDAQ: APDN) (after the close)
  • INmune Bio Inc (NASDAQ: INMB) (after the close)
  • Dare Bioscience Inc (NASDAQ: DARE) (after the close)
  • Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close)
  • Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close)
  • Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close)
  • Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close)
  • TFF Pharmaceuticals Inc (NASDAQ: TFFP) (after the close)
  • Viveve Medical Inc (NASDAQ: VIVE) (after the close)
  • Salarius Pharmaceuticals Inc (NASDAQ: SLRX) (after the close)
  • Vermillion, Inc. (NASDAQ: VRML) (after the close)


  • Digirad Corporation (NASDAQ: DRAD) (before the market open)
  • Zyla Life Sciences (OTC: ZCOR) (before the market open)
  • PLx Pharma Inc (NASDAQ: PLXP) (before the market open)

IPO Quiet Period Expiry

ORIC Pharmaceuticals Inc (NASDAQ: ORIC)


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Penny Stocks Previews FDA Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at